A biomarker-guided predictive care company, Bodyport, showed that its FDA-cleared, non-invasive technology for remote heart failure monitoring detected twice as many heart failure events when compared to current standard of care. Data were presented at the third annual Technology and Heart Failure Therapeutics conference in Boston. During the study, the congestion index correctly predicted 48 of 69 heart failure events (70%), demonstrating higher sensitivity (p<0.01) than the weight-scale standard of care.

Reference: Diagnostic and Interventional Cardiology. Bodyport Presents Preliminary Analysis of SCALE-HF 1 Study on Remote Heart Failure Monitoring at Technology and Heart Failure Therapeutics (THT) Conference. Published March 6, 2024. Accessed June 10, 2024. https://www.dicardiology.com/content/bodyport-presents-preliminary-analysis-scale-hf-1-study-remote-heart-failure-monitoring